AI Data Insight
In the fourth quarter of 2025, US imports of medicinal, dental, and pharmaceutical products dropped to 50,870 million USD, showing a significant decline from the previous quarter and halving from the high point earlier in the year. Constrained by the Trump administration's strict pharmaceutical tariff policies and pressures for localized manufacturing, international pharmaceutical companies have accelerated the adjustment of their supply chains, leading to a substantial cooling in the momentum of US pharmaceutical imports.